Part I will evaluate the pharmacokinetic profile and safety of KTN3379 over several doses with the objective of defining a Phase 2 dose in patients with advanced malignancies. Part II will evaluate the pharmacokinetic profile and safety of KTN3379 in combination with other targeted agents and obtain preliminary evidence of anti tumor activity in specific types of cancer. Patients will continue receiving KTN3379 alone or in combination until disease progression or toxicity that necessitates discontinuation (whichever comes first).
Name: KTN3379Description: Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive diseaseType: Biological
KTN3379 Part II, Arm A Part II, Arm B Part II, Arm C Part II, Arm D
Description: Continued assessment of safetyMeasure: Dose limiting toxicities for KTN3379 alone or in combination Time: Participants will be followed for the duration of treatment, an expected average of 3 cycles/9 weeks
Single Group Assignment
There is one SNP
Part II Arm A have head and neck cancer or K-Ras wild type EGFR expressing colon cancer, Arm B, have non small cell lung cancer, Arm C, have BRAF V600E mutated melanoma and Arm D have HER2 positive breast or gastric cancer that has progressed following one or more treatments for advanced or metastatic disease. --- V600E ---